Cargando…
Should radioiodine now be first line treatment for Graves’ disease?
BACKGROUND: Radioiodine represents a cost-effective treatment option for Graves’ disease. In the UK, it is traditionally reserved for patients who relapse after initial thionamide therapy. In a change from current practice, the new guidelines of the National Institute for Health and Care Excellence...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061474/ https://www.ncbi.nlm.nih.gov/pubmed/32165924 http://dx.doi.org/10.1186/s13044-020-00077-8 |